Annovis Awarded $1.7 Million NIH Grant for ANVS401 Chronic Toxicology Studies
27 févr. 2020 06h45 HE
|
Annovis Bio Inc.
BERWYN, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s (AD) , Parkinson’s (PD) and other...